Martin & Co. Inc. TN Takes $5.26 Million Position in Omnicell, Inc. $OMCL

Key Points

• Martin & Co. Inc. TN purchased 126,712 Omnicell shares worth approximately $5.26 million, representing about 0.28% of the company and 0.8% of the firm’s portfolio. Institutional investors collectively own 97.70% of Omnicell.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $57.86 price target, although Piper Sandler and Wells Fargo recently lowered their targets.
• Omnicell’s latest quarterly results exceeded expectations, with EPS of $0.94 versus the $0.47 estimate and revenue of $312.21 million, up 7.4% year over year. The stock opened at $35.58, near the lower end of its 52-week range.

Martin & Co. Inc. TN purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 126,712 shares of the company's stock, valued at approximately $5,261,000. Omnicell accounts for about 0.8% of Martin & Co. Inc. TN's portfolio, making the stock its 23rd biggest holding. Martin & Co. Inc. TN owned about 0.28% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Omnicell in the 2nd quarter valued at about $313,044,000. Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 6.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock worth $81,791,000 after purchasing an additional 137,834 shares during the period. Wellington Management Group LLP raised its position in shares of Omnicell by 156.4% in the fourth quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company's stock valued at $94,014,000 after buying an additional 1,265,818 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company's stock valued at $50,225,000 after buying an additional 62,733 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Omnicell by 2.0% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company's stock valued at $47,095,000 after buying an additional 27,497 shares during the period. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of analyst reports. Piper Sandler reissued an "overweight" rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Wall Street Zen upgraded Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 10th. Wells Fargo & Company decreased their price target on Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Craig Hallum reaffirmed a "buy" rating and issued a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $57.86.

Omnicell Stock Up 0.2%

NASDAQ OMCL opened at $35.58 on Friday. The business has a fifty day moving average price of $40.38 and a two-hundred day moving average price of $39.68. The stock has a market capitalization of $1.62 billion, a PE ratio of 42.36, a PEG ratio of 0.89 and a beta of 0.98. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company had revenue of $312.21 million during the quarter, compared to analysts' expectations of $310.21 million. During the same quarter in the previous year, the firm earned $0.45 EPS. Omnicell's revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities analysts expect that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source